Contrast agents for myocardial perfusion imaging
View Patent ↗The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
1. A contrast agent comprising an imaging moiety and an open-chain deguelin analog, wherein the open-chain deguelin analog is an analog of deguelin having the structure:
and at least one of rings C and D is not present or is replaced by a linker connecting the remaining rings.
2. A method of imaging myocardial perfusion, comprising:
administering to a patient a contrast agent which comprises an imaging moiety and an open-chain deguelin analog; and
scanning the patient using diagnostic imaging, wherein the open-chain deguelin analog is an analog of deguelin having the structure:
and at least one of rings C and D is not present or is replaced by a linker connecting the remaining rings.
3. The method of claim 2 wherein the imaging moiety is a radioisotope for use in nuclear medicine imaging, a paramagnetic species for use in MRI imaging, an echogenic entity for use in ultrasound imaging, a fluorescent entity for use in fluorescence imaging, or a light-active entity for use in optical imaging.
4. A contrast agent of formula (III):
J is S, C(R 37 ) 2 , or O;
------ is a single or double bond; and
R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are independently at each occurrence hydrogen, C 1 -C 6 alkyl optionally substituted with an imaging moiety, C 1 -C 6 alkoxy optionally substituted with an imaging moiety, or an imaging moiety; provided that when ------ is a double bond, R 31 and R 32 are absent; and
provided at least one imaging moiety is present in formula (III).
5. The contrast agent of claim 4 , wherein the imaging moiety is a radioisotope for use in nuclear medicine imaging, a paramagnetic species for use in MRI imaging, an echogenic entity for use in ultrasound imaging, a fluorescent entity for use in fluorescence imaging, or a light-active entity for use in optical imaging.
6. The contrast agent of claim 4 , wherein R 36 , R 37 , R 38 , or R 42 is an imaging moiety.
7. The contrast agent of claim 4 , wherein R 38 is an imaging moiety.
8. The contrast agent of claim 4 , wherein the contrast agent is:
9. The contrast agent of claim 4 , wherein the contrast agent is:
10. The contrast agent of claim 4 , wherein the contrast agent is:
11. The contrast agent of claim 4 , wherein the contrast agent is:
12. A method of imaging myocardial perfusion, comprising:
administering to a patient a contrast agent; and
scanning the patient using diagnostic imaging, wherein the contrast agent is of formula (III):
J is S, C(R 37 ) 2 , or O;
------ is a single or double bond; and
R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are independently at each occurrence hydrogen, C 1 -C 6 alkyl optionally substituted with an imaging moiety, C 1 -C 6 alkoxy optionally substituted with an imaging moiety, or an imaging moiety; provided that when ------ is a double bond, R 31 and R 32 are absent; and
provided at least one imaging moiety is present in formula (III).
13. The method of claim 12 , wherein the imaging moiety is a radioisotope for use in nuclear medicine imaging, a paramagnetic species for use in MRI imaging, an echogenic entity for use in ultrasound imaging, a fluorescent entity for use in fluorescence imaging, or a light-active entity for use in optical imaging.
14. The method of claim 12 , wherein R 36 , R 37 , R 38 , or R 42 is an imaging moiety.
15. The method of claim 12 , wherein R 38 is an imaging moiety.
16. The method of claim 12 , wherein the contrast agent is:
17. The method of claim 12 , wherein the contrast agent is:
18. The method of claim 12 , wherein the contrast agent is:
19. The method of claim 12 , wherein the contrast agent is: